<DOC>
	<DOCNO>NCT01736917</DOCNO>
	<brief_summary>The hypothesis substitution multi-day oral aprepitant ( intravenous ) IV fosaprepitant , combination 5-HT3 receptor antagonist ( 5HT3RA ) + dexamethasone provide comparable protection 5 day cisplatin chemotherapy induce nausea vomiting , compare result prior study aprepitant . This study first clinical trial evaluate fosaprepitant patient receive multi-day cisplatin . This single arm , phase II study . The investigator propose utilize intravenous ( IV ) fosaprepitant day 3 5 5-day cisplatin chemotherapy regimen . It anticipate fosaprepitant suppress delay chemo-induced nausea vomit 2-5 day therapy . This study test value fosaprepitant patient population .</brief_summary>
	<brief_title>Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone Germ Cell Tumors</brief_title>
	<detailed_description>OUTLINE : This multi-center study . Treatment Regimen : Patients must nausea and/or vomit 24 hour must use anti-emetics 72 hour prior start protocol treatment . Treatment must start criterion satisfied . Any germ cell chemotherapy regimen utilize cisplatin ( 20mg/m^2 x 5 day ) . This usually combine bleomycin ( BEP ) , etoposide ( EP ) , ifosfamide ( VIP ) , vinblastine ( VeIP ) , paclitaxel ( TIP ) epirubicin . All regimens get identical cisplatin , highly emetic drug chemo regimen . Acute emesis prophylaxis ( administer per institutional standard prior chemotherapy ) : - Any 5HT3 receptor antagonist may use day 1 5 day 1 , 3 5 palonosetron use per institutional standard . - Dexamethasone 20mg PO ( orally ) daily , day 1 2 - Fosaprepitant 150mg IV day 3 Delayed emesis prophylaxis : - Fosaprepitant 150mg IV day 5 - Dexamethasone 4mg PO BID ( twice day ) day 6 , 7 8 PRN ( need ) antiemetic allow discretion treat investigator - No additional dose 5HT3 receptor antagonist , dexamethasone , fosaprepitant give acute delay treatment period ECOG Performance Status 0-2 Life Expectancy : Not specify Hematopoietic : - White blood cell count ( WBC ) &gt; 3.0 K/mm3 - Absolute neutrophil count ≥ 1.5 K/mm3 - Hemoglobin ( Hgb ) &gt; 10 g/dL - Platelets &gt; 100 K/mm3 Hepatic : - Bilirubin &lt; 1.5 x ULN ( upper limit normal ) - Aspartate aminotransferase ( AST , SGOT ) ≤ 3 x ULN - Alanine aminotransferase ( ALT , SGPT ) ≤ 3 x ULN Renal : - Creatinine ≤ 2 mg/dl</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<criteria>Male patient ≥15 year age histologically cytologically confirm diagnosis germ cell tumor receive standard 5 day cisplatin base chemotherapy regimen . Prior chemotherapy allow . Patients chemo naïve . Written inform consent HIPAA authorization release personal health information . Patients must nausea vomit 24 hour antiemetic use 72 hour prior start protocol therapy . Treatment must start registered patient criterion meet . No active central nervous system ( CNS ) metastasis . Patients neurological symptom must undergo head CT scan brain MRI exclude brain metastasis . NOTE : A patient prior brain metastasis may consider complete treatment brain metastasis , long require corticosteroid , asymptomatic . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , Gleason &lt; grade 7 prostate cancer , cancer patient diseasefree least 1 year . No previous treatment investigational agent within 30 day prior registration protocol therapy . No concurrent participation clinical trial involve another investigational agent . No use agent expect induce metabolism fosaprepitant include : rifampin , rifabutin , phenytoin , carbamazepine , barbiturate . No concurrent use agent may inhibit metabolism fosaprepitant include : cisapride , macrolide antibiotic ( erythromycin , clarithromycin , azithromycin ) , azole antifungal agent ( ketoconazole , itraconazole , voriconazole , fluconazole ) , amifostine , nelfinavir , calcium channel antagonists verapamil diltiazem , ritonavir . No concurrent use warfarin study . No known history anticipatory nausea vomit . No clinically significant infection judge treat investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Fosaprepitant</keyword>
	<keyword>5HT3 Receptor Antagonists</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Germ Cell Tumors</keyword>
	<keyword>Testis Cancer</keyword>
	<keyword>Rescue Medications</keyword>
</DOC>